Circio fundamentale forhold (CRNA, tidl. TRVX)

[TekBot]

Targovax ASA: Registration of share capital increase following conversion of convertible bonds

Oslo, 13 April 2023: Reference is made to the stock exchange announcement by
Targovax ASA (OSE:TRVX) (“Targovax” or the “Company”) on 30 March 2023,
regarding the board of directors’ resolution to increase the share capital of
…

Vis børsmeldingen

the Company in connection with the conversion of convertible bonds.

The share capital increase has now been registered with the Norwegian Register
of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share
capital is NOK 19,260,420.10, divided into 192,604,201 shares, each with a par
value of NOK 0,10.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Kilde

[TekBot]

Targovax ASA: Annual Report 2022

On 13 April 2023, the Board of Directors of Targovax ASA approved the Company’s
Annual Report, including the financial statements for 2022, which will be
processed at the Company’s annual general meeting on 22 May 2023. Targovax ASA
…

Vis børsmeldingen

also publishes today its annual financial statements in the European Single
Electronic Format (ESEF), which is available as an attachment to this release.

The documents are also available at the Company’s website,
www.targovax.com (Financial Reports – Targovax).

Changes from Q4 2022 Interim Financial Report to Annual Accounts

After publishing the Q4 2022 report, Targovax has made some changes to the YTD
2022 figures initially reported in the Q4 interim report.

The adjustments mainly relate to impairment done for accounting purposes as the
company has made the decision to only proceed with the phase 2 program of ONCOS
-102 once an additional partner or additional source of financing has been
secured.

Subsequent to this decision, the recognized intangible asset of NOK 391 million,
related to the acquisition of Oncos Therapeutics OY in 2015, was therefore fully
impaired as of 31 December 2022. Hence, the remaining fair value adjustments of
the Business Finland loans of NOK 1 million and the recognized deferred tax
liability as per 31 December 2022 of NOK 60 million, also related to the
acquisition of Oncos Therapeutics OY in 2015, was derecognized.

This has resulted in decreased assets of NOK 391 million, decreased equity of
330 million, decreased liabilities of NOK 61 million and increased loss after
taxes of NOK 330 million for the period being reported in the annual financial
statements compared to what was reported in the Q4 2022 Interim financial
report.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Kilde

[TekBot]

Targovax skifter navn til Circio og styrker satsingen på sirkulært RNA

· Navnet Circio befester satsingen på den innovative sirkulær RNA-plattformen
(circRNA)
· circRNA har potensiale som et neste generasjons mRNA, og Circio satser i
…

Vis børsmeldingen

første omgang på behandling av kreft og utvikling av vaksiner
· Circio Holding ASA vil videreføre børsnoteringen til Targovax ASA på Oslo
Børs under tickeren CRNA

Oslo, 19. april 2023 - Targovax ASA (OSE: TRVX) endrer navn til Circio for å
reflektere selskapets nye, spissede satsing på utvikling av den innovative
circRNA plattformen. Betinget av vedtak på generalforsamlingen 22. mai 2023 vil
selskapets nye navn bli Circio Holding ASA og gruppens børsnotering på Oslo Børs
vil videreføres under tickeren CRNA.

• Endringen til Circio understreker vår ambisjon om å bli ledende innen circRNA,
  samtidig som det bygger på vår bakgrunn fra immunterapi. circRNA anses som svært
  lovende innen ny RNA-medisin, illustrert av flere betydelige internasjonale
  finansieringer og avtaler. De siste to årene har 40% av investert kapital innen
  RNA-kategorien gått til circRNA, og store legemiddelselskaper posisjonerer seg
  nå innenfor området. Med navnebyttet til Circio vil vi bli mer synlige og
  attraktive for både industrielle partnere og spesialistinvestorer, sier
  styreleder Damian Marron.

circRNA er en naturlig forekommende klasse av RNA oppdaget i 2011 av to Circio
-ansatte, forskningssjef dr. Thomas B. Hansen og adm.dir. dr. Erik Digman
Wiklund. circRNA er resistent mot de viktigste mekanismene for nedbrytning av
RNA, og derfor langt mer stabilt enn lineært mRNA. Denne egenskapen muliggjør
høyere og mer langvarig uttrykk av proteiner, samt inkorporering av nye
regulatoriske funksjoner. Circio arbeider med en rekke circRNA baserte
behandlingskonsepter innenfor kreft, vaksiner og genterapi, og det er søkt om
internasjonale patenter for å beskytte teknologien. Forskning og utvikling
foregår i det heleide datterselskapet Circio AB ved Karolinska Institutet i
Stockholm.

• circRNA er svært stabilt og har potensiale til å bli mRNA 2.0. Vår forskning
  er ledet av oppdagerne av circRNA, og basert på deres brede erfaring innen
  feltet har vi etablert en unik teknologisk plattform. Ved å bruke et DNA-basert
  vektor-system gir vi kroppen instruksjoner for å selv produsere circRNA, og på
  den måten kan vi gjøre pasientens egne celler til circRNA fabrikker. Dette gir
  oss flere fordeler og muligheter innen nye terapeutiske områder som det i dag er
  krevende å behandle med RNA-medisiner, sier dr. Erik Digman Wiklund,
  administrerende direktør i Circio.

Circio vil parallelt fortsette utviklingen av selskapets kliniske programmer TG
og ONCOS. To eksternt finansierte samarbeidsstudier med kreftvaksinen TG01 pågår
i USA og Norge i RAS-mutert kreft. En fase 2 studie med ONCOS-102 i føflekkreft
er godkjent av amerikanske myndigheter, og vil starte når ekstern finansiering
eller en partner er identifisert.

Navneendringen fra Targovax ASA til Circio Holding ASA er betinget av vedtak på
selskapets generalforsamling den 22. mai 2023.

For mer informasjon, vennligst kontakt:
Erik Digman Wiklund, CEO
Telefon: +47 413 33 536
Epost: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Telefon: +47 922 61 624
Epost: renate.birkeli@circio.com (renate.birkeli@targovax.com)

Media forespørsler:
Andreas Tinglum - Corporate Communications (Norway)
Telefon: +47 9300 1773
Epost: andreas.tinglum@corpcom.no

Kilde

[TekBot]

Targovax ASA - Notice of Annual General Meeting

The Annual General Meeting of Targovax ASA (the “Company”) will be held at the
Company’s offices at Lysaker, on 22 May 2023 at 14:00 CET.

…

Vis børsmeldingen

Notice of attendance

Notice of attendance must be received no later than 19 May 2023 at 16:00 CET.

Casting of advance votes and submission of proxies must be received no later
than 19 May 2023 at 16:00 CET.

Attached you will find the notice to the General Meeting, including appendices.
The notice and appendices will also be made available on Targovax’ website
https://www.circio.com/en/section/governance/general-meetings/.

TRVX - Notice AGM
22.05.2023.pdf (https://mb.cision.com/Public/17093/3760492/9cfd8b6da207cdd7.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Kilde

[TekBot]

Circio: circRNA poster to be presented at the ASGCT Annual Meeting

Oslo, Norway, 3 May 2023 - Circio Holding ASA (formerly Targovax ASA*) (OSE:
TRVX) today announces that an abstract describing its circular RNA platform has
been accepted for poster presentation at the 2023 American Society of Gene +
…

Vis børsmeldingen

Cell Therapy (ASGCT) Annual Meeting in Los Angeles, USA.

The abstract describes the development of Circio’s proprietary circAde vector
system for therapeutic protein expression. Key elements necessary for circRNA
biogenesis were systematically screened and optimized to facilitate high yield
circRNA expression. Additionally, protein expression from the circAde vector was
found to outperform conventional mRNA-based designs, both in terms of protein
expression level and durability in vitro. Our results highlight the potential of
the circAde platform for the development of novel, more effective strategies for
the treatment of diseases in which durable transgene expression is desirable.

The poster is scheduled for presentation Thursday 18 May 2023 and will be
available on Circio’s website (https://www.circio.com/en/oncos-oncolytic-virus
-publications-posters-and-oral-presentations/) after the presentation.

Poster circAde, a Vector System for Spliceosome Dependent circRNA
title: Biogenesis and Prolonged More Effective Protein Expression
Date and Thursday 18 May 2023, 12:00- 13:30 PDT / 21:00-22:30 CEST
time:
Location: The Los Angeles Convention Center in Los Angeles, CA
Poster 1095
number:
Presenter: Eoghan O’Leary, Director RNA Research

About ASGCT

The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is the
premier event for professionals in gene and cell therapy. The meeting is the
best place for people in the field to learn from the latest scientific research,
stay up to date on new technologies, and make career-advancing connections with
peers.

Originally designed as a venue for academic researchers to share their work, the
Annual Meeting has grown to serve a wide community encompassing clinicians, bio
-industry development, regulatory agencies, equipment manufacturers, patient
advocates, and more.

*) Targovax ASA, which is changing its company name to Circio Holding ASA, has
called for an AGM on 22 May 2023, to vote for the approval of the change of its
company name from Targovax ASA to Circio Holding ASA.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Building on deep experience in RNA biology, immunotherapy and viral vector
engineering, Circio has established a unique circular RNA (circRNA) platform to
develop novel circRNA medicines for cancer, vaccines, protein replacement for
genetic disorders and cell therapy. The proprietary circVec technology is based
on a modular genetic cassette design for efficient biogenesis of multifunctional
circRNA from DNA-based vectors that can be deployed for multiple purposes. The
most advanced therapeutic concept, circAde, builds on the company´s experience
in oncolytic viruses to use engineered adenoviruses for delivery of circRNA to
cancer cells. This unique approach is the only currently known circRNA program
targeting solid tumors. Circio´s strategy is to develop novel circAde cancer
medicines in-house and seek partnerships in other therapeutic areas to
demonstrate the broad potential of the circVec platform and accelerate our
circRNA pipeline development. The circRNA R&D activities are being conducted by
the wholly owned subsidiary Circio AB based at the Karolinska Institute in
Stockholm, Sweden.

Circio´s clinical immunotherapy programs are designed to activate the patient´s
own immune system to fight cancer cells and provide benefit to patients with no
or few treatment alternatives. Lead candidate ONCOS-102 is an oncolytic
adenovirus (AdV5) carrying a genetic cassette for mRNA-based expression of the
cytokine GM-CSF, designed to selectively target cancer cells and drive an anti
-tumor immune response. ONCOS-102 has demonstrated an excellent safety profile,
strong immune responses and clinical efficacy in several cancer types in Phase
1/2 studies, both as monotherapy and in combinations with checkpoint inhibitors
or standard-of-care chemotherapy. Circio is aiming to progress ONCOS-102 into a
phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor
treatment, subject to additional external financing and/or partnerships to
support the program.

Circio’s second clinical stage program is an immunotherapy targeting KRAS driver
mutations. Lead candidate TG01 has previously shown robust immune responses and
encouraging clinical benefit in surgically resected pancreatic cancer, and is
currently being tested in two clinical trials in RAS-mutated pancreatic cancer
and multiple myeloma in the USA and Norway. These studies are being run through
industry and academic collaborative networks, supported by prestigious research
grants from Innovation Norway and the Norwegian Research Council, creating broad
future optionality for the TG01 program at low cost to Circio.

Kilde

[TekBot]

Targovax ASA - Correction of the proxy form attached to the notice of the Annual General Meeting

Reference is made to the stock exchange notice published on 28 April 2023 where
Targovax ASA (the “Company”) published the notice of the annual general meeting
to be held at the Company’s offices at Lysaker, on 22 May 2023 at 14:00 hours
…

Vis børsmeldingen

(CEST).

The matters on the agenda were erroneously numbered in the original proxy forms
attached to the notice (Appendix 1) in both the Norwegian and English versions
of the notice and in VPS.

Please find attached a revised proxy form where this has been corrected. No
revision has been made to the notice. The revised Appendix 1 replaces the
original Appendix 1 in its entirety. The numbering has also been corrected in
VPS.

The voting reflected in the advanced votes and the proxies already received will
be adjusted to the corrected numbering (i.e., votes relating to items 11 and 14
in the original proxy forms will be disregarded).

The notice and appendices are also available on Targovax’ website
General Meetings – Circio

TRVX - Notice AGM
22.05.2023 (https://mb.cision.com/Public/17093/3762781/b6075f15eaf82750.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Kilde

[TekBot]

Circio invites to a company update on Tuesday 16 May 2023

Oslo, Norway, 12 May 2023 - Circio Holding ASA (formerly Targovax ASA*) (OSE:
TRVX):

…

Vis børsmeldingen

Circio’s management and Board of Directors invite to a live webcast on Tuesday
16 May at 10am CEST. In the webcast, CEO Erik D. Wiklund will provide a brief
company update, followed by a Q&A session with representatives from the
Compensation and Nomination Committee regarding the upcoming annual general
meeting (AGM) and proposed resolutions.

Date: Tuesday 16 May 2023
Time: 10.00 CET
Webcast Click here for teams link (https://teams.microsoft.com/l/meetup
link: -join/19%3ameeting_ZmJkYTViY2QtMjYyNS00N2NkLWE1NWQtYTQyMzhmMjM4M
jYy%4
0thre
ad.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966
-5b0cce82b3fe%22%2c%22Oid%22%3a%22f1f4b1fb-51b3-4160-8c7e
-64dc6bdf46bb%22%7d)
Presenters: Erik Digman Wiklund, CEO
Thomas Falck, Board member and Chair of the Compensation
Committee
Ludvik Sandnes, Chair of the Nomination Committee

Please submit any questions in advance to renate.birkeli@circio.com or directly
during the live webcast.

Questions can be made in English or Norwegian and will be addressed in the
respective language.

• Targovax ASA, which is changing its company name to Circio Holding ASA, has
  called for an AGM on 22 May 2023, to vote for the approval of the change of its
  company name from Targovax ASA to Circio Holding ASA.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Building on deep experience in RNA biology, immunotherapy and viral vector
engineering, Circio has established a unique circular RNA (circRNA) platform to
develop novel circRNA medicines for cancer, vaccines, protein replacement for
genetic disorders and cell therapy. The proprietary circVec technology is based
on a modular genetic cassette design for efficient biogenesis of multifunctional
circRNA from DNA-based vectors that can be deployed for multiple purposes. The
most advanced therapeutic concept, circAde, builds on the company´s experience
in oncolytic viruses to use engineered adenoviruses for delivery of circRNA to
cancer cells. This unique approach is the only currently known circRNA program
targeting solid tumors. Circio´s strategy is to develop novel circAde cancer
medicines in-house and seek partnerships in other therapeutic areas to
demonstrate the broad potential of the circVec platform and accelerate our
circRNA pipeline development. The circRNA R&D activities are being conducted by
the wholly owned subsidiary Circio AB based at the Karolinska Institute in
Stockholm, Sweden.

Circio´s clinical immunotherapy programs are designed to activate the patient´s
own immune system to fight cancer cells and provide benefit to patients with no
or few treatment alternatives. Lead candidate ONCOS-102 is an oncolytic
adenovirus (AdV5) carrying a genetic cassette for mRNA-based expression of the
cytokine GM-CSF, designed to selectively target cancer cells and drive an anti
-tumor immune response. ONCOS-102 has demonstrated an excellent safety profile,
strong immune responses and clinical efficacy in several cancer types in Phase
1/2 studies, both as monotherapy and in combinations with checkpoint inhibitors
or standard-of-care chemotherapy. Circio is aiming to progress ONCOS-102 into a
phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor
treatment, subject to additional external financing and/or partnerships to
support the program.

Circio’s second clinical stage program is an immunotherapy targeting KRAS driver
mutations. Lead candidate TG01 has previously shown robust immune responses and
encouraging clinical benefit in surgically resected pancreatic cancer, and is
currently being tested in two clinical trials in RAS-mutated pancreatic cancer
and multiple myeloma in the USA and Norway. These studies are being run through
industry and academic collaborative networks, supported by prestigious research
grants from Innovation Norway and the Norwegian Research Council, creating broad
future optionality for the TG01 program at low cost to Circio.

Kilde

[Birgitte]

Det er bra. Info til eierne er viktig. Så får vi se om de er furnuftige nok til å endre forslaget om fullmakt til styret.

Det er ingen oppgående eier som bør stemme for en slik dynamisk økende fullmakt på 10% etter at de allerede og bare på 1 år forsynte seg av hele 2,4% av selskapet.

[Xon]

Det er greit at du har en egen mening, men det er ingen grunn til å harselere med de som har en annen mening enn deg.

Det er nok nå …

[Birgitte]

Pass på “lommeboka” di Xon ellers tømmer de den snart

[Haltopen]

@Xon

Det er greit at du har en egen mening, men det er ingen grunn til å harselere med de som har en annen mening enn deg.

Sier personen bak poop emojis på innlegg hen er uenig med.

[Xon]

En oppegående person er en som er ressurssterk og velfungerende i samfunnet, klarer seg selv fint og/eller er særdeles flinke til å se andres behov og hjelpe disse.

En ikke oppegående person er det motsatte …

Enkelte innlegg premieres iblant med en eller en avhengig av kvaliteten på innlegget … ikke nødvendigvis om man er enig eller ikke.

Det er sunt med ulike meninger, men det er en grense hva som oppfattes som seriøst.

Håper dette forklarer mitt innlegg.

[solskimm]

Dagens eiere har i dag null innflytelse på Targovax, å har ikke hatt det på mange år. Nå er det jaggu på tide å gi det administrasjonsstyrte selskapet noen føringer på hva som er å ikke er innafor.

[anon13721814]

Det er litt oppsiktsvekkende at de skal ha en “company update” med representanter fra de som setter lønn og annen kompensasjon. Er dette virkelig noe de skal bruke tid og energi på? For meg handler dette enkelt om at TRVX/Circio ikke har råd til kostbare bonusordninger nå.

[sjog]

Spørs om de ansatte må kjøpe seg noen aksjer så de får stemt gjennom forslagene sine. Opsjoner har som kjent ingen stemmerett

[Pk2k]

Company update faktisk her jobbes det hardt for å beholde de gode ordningene

[Freddys]

@TekBot

Presenters: Erik Digman Wiklund, CEO
Thomas Falck, Board member and Chair of the Compensation
Committee
Ludvik Sandnes, Chair of the Nomination Committee

Rart at Ludvik Sandnes skal snakke? Eller?
Han virket lite imponert over «targovax» sin strategi med Atlas, under sin nano presentasjon.

[anon79663630]

Kan det være at noen har spilt inn benkeforslag til styret, eller at stemmene så langt tyder på at noen ligger tynt an slik at vedtektene ikke kan oppfylles ?

[sjog]

Det kan tyde på at forhåndsstemmene har gjort ledelsen bekymret ja. Noen annen årsak til denne “update” er vanskelig å se.

[solskimm]

Nå får Wiklund tenke på hvor høy risiko det er å ikke investere i eget selskap fremfor å bare tappe det og kjøre i gang dødsspirallån.